Anavex Life Sciences (AVXL) is poised to make MASSIVE gains over the next two weeks. I posted about AVXL’s potential about a month ago when it was trading at $12.50. Currently AVXL closed on Friday at $14.50 (roughly a 15% increase over the 25 days).
After many years of trials with the same drug platform (Anavex 2-73) across multiple central nervous system diseases (Rett, Parkinsons, Alzheimer, and others), the platform has had positive results across all trials….no failures. In fact, their Rett drug has been granted Orphan Drug Status AND in just the last few weeks their drug was granted Orphan Drug Status for Fragile X. Just as importantly the safely profile has been excellent across all trials over 5 plus years, in many countries across the globe.
In short, all looks very positive. We are now in the perfect storm that could skyrocket the share price 10 to 20x in a matter of days.
AVXL has announced a late breaking poster presentation at the prestigious CTAD conference on Dec 1…they have committed to delivering top line results for the current Alzheimer phase 2/3 trial at this scientific conference https://www.anavex.com/post/anavex-life-sciences-announces-late-breaking-presentation-at-the-2022-ctad-congress
If you look at the agenda, Anavex has 7 of their top executives from around the globe presenting…several world renown experts in their fields (McFarlane Rett etc). This is a HUGE deal. This event puts a stake in the ground for results that have been promised for this year.
Assuming positive results its possible/likely you could see the stock jump from the current (as of Friday) $14.50 to well over $100 per share by Dec 1st.
The market value for a successful AD trial has already been pegged AT A MINIMUM $20 billion, as seen by BIIB and their recently announced AD trial results….it added $20 Billion to the market cap overnight. The problem with BIIB is the side effects that include significant brain swelling (Biogen Inc.'s controversial Alzheimer's drug Aduhelm produced brain swelling in 35% of patients who took the approved dose, ) …
AVXL has none of that. Given a successful trial outcome with a clean safety profile, AVXL could command a $40 billion plus market cap.
You need to understand that a clean safely profile AD drug that works will become the largest selling drug in the world. Another industry player, SAVA, spiked from about $10 per share to over $120 all within a week over the last 24 months.
Now its AVXL’s turn.
Now that you have small back drop..and you can do plenty of your own research, consider the following:
- Low float (78 million shares),
- Modest market cap compared to market upside (approx. 1 Billion now..with short term target of $20billion plus).
- Shares short are about 10 million shares.
- The stock has had significant volume increase in the last 3 trading days…and the share price has started to move.
If you look at the bread crumbs, why would AVXL announce a late breaking presentation in late October, for a Dec 1st presentation of AD trial results..and have their full team there unless there was a strong update on the trial results. In addition CTAD is a SCIENTIFIC conference not an investor conference…and later breaking presentations have to be reviewed and accepted. Logic would say the CTAD staff determined it was meaningful enough for a special late breaking presentation.
AVXL has also indicated that a peer review publication will review/validate the trial results. Combine this with years of positive, safe, trial results…and evidence points heavily to upcoming dramatic and positive set of results.
This week you will likely see the shorts starting to cover with strong volume. Look for AVXL to be in the $20’s (perhaps more) before CTAD (Dec 1st). And remember we have only spoken about the AD drug. The Rett and Parkinsons drug could add another another $150 plus per share…AVXL is a multidimensional CNS drug platform with trials and results to prove it.
This is one of those rare events that has the potential to make many people very rich and solve a big problem for humanity.
Will you be part of it ? The shorts are in quite a box right now with a risk of loosing $100 to $200 per share. So watch the frying pan this week….and if you like to play..this one may be it….
Leave a Reply